Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467259 · ClinicalTrials.gov registry record · Phase 3
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,271
- Enrollment target
NCT00467259: Completed Phase 3 study, sponsored by Warner Chilcott.
NCT00467259 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 1,271 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00467259, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,271 participants
- Enrollment target
Study Summary
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
Primary Outcome
Incidence measured is number of patients with endometrial hyperplasia/number of patients with evaluable biopsies
Interventions
- DRUG Placebo patch
- DRUG Testosterone Transdermal System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,271 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
What the finished NCT00467259 record still lists
NCT00467259 is an interventional study that assigns participants to a tested intervention. Its 1,271 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo patch is the first listed.
NCT00467259 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00467259 about?
NCT00467259 is a clinical study titled "Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women". This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
What is the current status of trial NCT00467259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,271 participants. The study started on 2007-04. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00467259?
The interventions under investigation include: Placebo patch (DRUG), Testosterone Transdermal System (DRUG).
Who is sponsoring clinical trial NCT00467259?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00467259's enrollment target sits among peer trials
1,271 202nd of 2000 higher than 1,799 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790641 · 1,270 participants · NA
Pathways to Perinatal Mental Health Equity
- NCT06876246 · 1,270 participants · NA
SBIR/ STTR Family Check-up Online
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- NCT07225504 · 1,275 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia